Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED.WR | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Comment by stanleyon Sep 27, 2013 9:20am
401 Views
Post# 21772456

RE:RE:WD's Presentation at the Denver Gold Forum

RE:RE:WD's Presentation at the Denver Gold ForumLurk & Learns:

RE: Operating Statistics on pg 21 of Denver Gold presentation:

Sometimes putting certain events into their proper perspective MAY help to attract/retain shareholder interest. Case in point is explaining in print on page 21 a footnote to explain the drop in mill throughput to 1,700 tpd. After a long conference potential investors may not be able to make connection of the lower number versus previous quarters.

1. After we remove the vertical line to the right of the 2013 Actual header to show that it covers H1 (Q1 & Q2)... we may want to show a Q2 footnoted to reflect the 19 days lost due to the spring run-off issue.

e.g. If we're looking at the 1700 tpd, we my wonder why the title of the slide is Operating vs Calender Statistics. Thus, we can make our own corrections in order to compare the Operating Stats of the previous quarters to Q2/2013. So we can take the 1,700 tpd and multiply it by the 91 calender days used (April, May & June) to get the total tonnes milled for the quarter. We then subtract the 19 down days from the calender days to get 72 ACTUAL operating days. If we divide the ACTUAL throughput by the ACTUAL operating days we get ~2150 tpd.

BWDIK? Sometimes putting "force majeur" type of events MAY put certain events into a positive light. In this case I would have expected another column of footnote.. Q2/13A (1) that shows them impact of the 19 down days. By doing so in would make it easier to compare ACTUAL Operating statistics. WD talked about 2000/2200/2400 by doing an adjusted for the 19 down days it would put the mill OPERATIONAL performance into the proper range.

Cheers
Stanley



Bullboard Posts